Sanjivani Parenteral Limited Reports FY26 Full-Year Results; EBITDA stood at Rs 114 mn with PAT at Rs 66.94 mn

Mumbai (Maharashtra) [India], May 15: Sanjivani Paranteral Limited (Sanjivani, The Company) (BSE:531569), one of the emerging players in the pharmaceutical and healthcare manufacturing sector, continued to strengthen its operational performance during the year through improved efficiencies, focused execution, and a customer-centric approach across its business segments, and has announced its Audited Financial Results for Q4 FY26.K

Key Consolidated Financial Highlights

Highlights

Q4 FY26

  • Total Income of ₹ 138.09 mn, 
  • EBITDA of ₹ 21.73 mn
  • EBITDA Margin of 15.74%
  • PAT of ₹ 5.48 mn
  • PAT Margin of 3.97%
  • EPS of ₹ 0.49

Segment-wise Performance:

  • Injectables: Revenue stood at ₹46.70 mn, contributing 44.43% of revenue from operations. 
  • Tablets: Revenue grew by ~11.1% YoY to ₹54.60 mn, with contribution increasing to 51.95% of revenue from operations. 
  • Nutraceuticals: Revenue stood at ₹3.81 mn, accounting for 3.62% of revenue from operations. 

Market-wise Performance:

  • Exports (incl. incentives): Contributed 85.26% of revenue from operations (₹89.62 mn), while domestic accounted for 14.74%.
  • Core markets (CIS, Middle East & Africa, Latin America): Contributed ~76.09% of revenue from operations, amounting to ~₹80.0 mn.

FY26

  • Total Income of ₹ 697.56 mn
  • EBITDA of ₹ 114.00 mn
  • EBITDA Margin of 16.34%
  • PAT of ₹ 66.94 mn
  • PAT Margin of 9.60%
  • EPS of ₹ 5.49

Segment-wise Performance:

  • Injectables: Revenue stood at ₹346.15 mn, contributing 53.45% of revenue from operations. 
  • Tablets: Revenue grew by Approx. 7.5% YoY to ₹279.14 mn, with contribution rising to 43.10% of revenue from operations. 
  • Nutraceuticals: Revenue stood at ₹22.35 mn, contributing 3.45% of revenue from operations. 

Market-wise Performance:

  • Exports (incl. incentives): Contributed 78.50% of revenue from operations (₹508 mn), while domestic contributed 21.50%. 
  • Core markets (CIS, Middle East & Africa, Latin America): Accounted for ~77.01% of revenue from operations, amounting to ~₹498.75 mn.

Commenting on the performance, Mr. Ashwani Khemka, Chairman & Managing Director of Sanjivani Paranteral Limited, said, “FY26 has been a year of steady operational progress and focused execution for Sanjivani Paranteral Limited. The commencement of commercial production at our newly established IV Fluid Infusion Plant in Pune marks a significant milestone in strengthening our manufacturing capabilities and expanding our healthcare product portfolio. Equipped with advanced technology and sustainable infrastructure, the facility is expected to improve operational efficiency, enhance product quality, and support growing demand across domestic and export markets.

Our continued focus on quality manufacturing, disciplined cost management, and long-term customer relationships has enabled us to maintain stable business performance in a dynamic operating environment. This expansion further strengthens our market presence and positions the Company for scalable and sustainable long-term growth as we move into FY27. We remain committed to evaluating new growth opportunities and strategic initiatives aimed at enhancing operational scale and creating long-term value for all stakeholders.”

About Sanjivani Paranteral Limited

Sanjivani Parenteral Limited (BSE: 531569) is engaged in the pharmaceutical and healthcare manufacturing business, with a focus on delivering quality products and maintaining strong operational standards. The Company continues to strengthen its presence through operational excellence, customer-centric execution, and continuous focus on quality and compliance.

With a commitment towards sustainable growth and long-term value creation, the Company continues to focus on enhancing manufacturing capabilities, improving efficiencies, and expanding its business presence across key markets.

For FY26, the company has reported Total Income of ₹ 697.56 mn, EBITDA of ₹ 114.00 mn & PAT of ₹ 66.94 mn on a consolidated basis.

Related Posts

Batman x Samsonite: Iconic DC Super Hero, Reimagined Through the Lens of Modern Travel

Mumbai (Maharashtra) [India], November 16: Samsonite, the global leader in travel, luggage and mobility solutions, announces a licensing partnership with Warner Bros. Global Consumer Products to launch a collection inspired…

How ISAK Fragrances Is Carrying 170 Years of Lucknow’s Perfumery Legacy Into Indian Luxury

A sixth-generation perfumer is building a modern fragrance house on a family craft that began in the courts of nineteenth-century Lucknow. New Delhi [India], November 16: In the 1850s, a…

You Missed

Ye Mahaveer Ka Panth Hai, Har Prani Me Sant Hai’ – Mahavir Nirvana Katha resonates at Bharat Mandapam

  • By
  • November 16, 2026
Ye Mahaveer Ka Panth Hai, Har Prani Me Sant Hai’ – Mahavir Nirvana Katha resonates at Bharat Mandapam

8th International HKL Conference Begins at Gurdwara Bulandpuri Sahib; Flags of 116 Nations Hoisted to Promote Global Unity

  • By
  • November 16, 2026
8th International HKL Conference Begins at Gurdwara Bulandpuri Sahib; Flags of 116 Nations Hoisted to Promote Global Unity

Arif Patel: Shaping a New Generation of Real Estate Development in Dubai, UAE

  • By
  • November 16, 2026
Arif Patel: Shaping a New Generation of Real Estate Development in Dubai, UAE

World Diabetes Day: Understanding the Role of Nutrition in Blood Sugar Management and the Benefits of American Pistachios

  • By
  • November 16, 2026
World Diabetes Day: Understanding the Role of Nutrition in Blood Sugar Management and the Benefits of American Pistachios

Why Colonialism Still Matters: Museum of British Colonialism to Host Online Panel Discussion on 19 November

  • By
  • November 14, 2026
Why Colonialism Still Matters: Museum of British Colonialism to Host Online Panel Discussion on 19 November

Dr. R. K. Thukral and the Work of Bringing Neuropsychiatry Closer to Patients

  • By
  • November 14, 2026
Dr. R. K. Thukral and the Work of Bringing Neuropsychiatry Closer to Patients